Zongertinib

6 trials 6 recruiting

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

6 Recruiting

0 Completed trials

3 Sponsors

16 Countries

Phase III

Phase II

Phase I/II

Phase III: 2 Phase II: 3 Phase I/II: 1

Oversight events:

2 serious breaches across 1 trial

View oversight register →

Indications tested

Non-small cell lung cancer 2 Oesophageal adenocarcinoma 1

Sponsors using this IMP

Boehringer Ingelheim International GmbH 5 Boehringer Ingelheim Espana S.A. 4 HUS-Yhtymae 1

All trials

6 total

FINACCESS - Finnish National Study for Early Access to Cancer Therapies Recruiting

2025-524769-26-00 Phase II 1 country HUS-yhtymae
Beamion 44: A study to test how well zongertinib is tolerated by people with advanced non-small cell lung cancer with HER2 mutations when gi… Recruiting

2025-523567-38-00 Phase II 3 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
Beamion BCGC-1: A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps … Recruiting

2023-509566-38-00 Phase I/II 5 countries Boehringer Ingelheim International GmbH
BEAMION Lung-2: A study to test whether zongertinib (BI 1810631) helps people with advanced non-small cell lung cancer with HER2 mutations c… Recruiting

2023-504308-27-00 Phase III 13 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
Beamion LUNG-3: A study to test whether zongertinib helps people with surgically removed, non-small cell lung cancer with HER2 mutations com… Recruiting

2025-521284-12-00 Phase III 12 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
Beamion PANTUMOR-1: A study to test whether zongertinib helps people with advanced cancers with HER2 alterations Recruiting

2023-510429-14-00 Phase II 7 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH

Showing 1–6 of 6 trials

← All drugs A–Z